Cost Curve

A New Tracker for Watching Meds That Might See Prices Slashed

And an evolving list of all of the pricing and policy fun to be had between now and Christmas

Brian Reid

Why IRA ‘Negotiations’ and MFN Dealmaking Led to Such Different Prices for Ozempic and Wegovy

And the 340B rebate model debate is coming to Cost Curve’s home turf: Portland

Brian Reid

Reimbursement for Hep B Shots Should Remain Stable Even as CDC Panel Undermines the Vaccine

And a STAT analysis suggests that major health insurers are seeing med spending skyrocket, but a closer look at the data raises questions

Brian Reid

A New Health Affairs Forefront Piece Seeks to Reset the ‘Pharm-to-Table’ Conversation

And lawmaker talk of PBM reform has returned. Will action follow?

Brian Reid

Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

Brian Reid

The Need-to-Know on a Slow News Day: More MFN Deals Are Coming, and Why Pharma Thinks the U.S./U.K. Trade Agreement Should Be a Model

Brian Reid

The U.K. Will Make Efforts to Boost Drug Prices in Return for the Elimination of U.S. Tariffs

And the pharm-to-table pricing of obesity medicines gets even more dizzying as Lilly cuts the price of Zepbound vials

Brian Reid

The Search for Clarity on the Differences Between IRA and MFN Prices for Ozempic and Wegovy

And an FDA official calls out ‘unique financial incentives for vaccine makers’

Brian Reid

Medicare Negotiated Prices Are Out for 15 More Drugs. Here’s What We Know

Brian Reid